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Abstract Infection of mammalian cells with picornaviruses like
entero-, rhino-, and aphthoviruses leads to an inhibition of cap-
dependent cellular protein synthesis by the cleavage of both
translation initiation factors, eIF4GI and eIF4GII. In entero-
and rhinovirus infection this cleavage process is mediated by the
viral 2A proteinase (2Apro). In order to discriminate between a
direct mode of eIF4G cleavage and an indirect cleavage via
activation of a cellular proteinase, a thermosensitive 2Apro mu-
tant (ts-2Apro) of human rhinovirus 2 was employed. Temper-
ature shift experiments of cytoplasmic HeLa cell extracts incu-
bated with ts-2Apro strongly support a direct mode of cleavage
of eIF4GI and eIF4GII by the viral 2Apro. & 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Many viruses have developed intricate strategies to manip-
ulate their host cells in order to promote their own replica-
tion. Picornaviruses, single-stranded RNA viruses of positive
polarity, encode proteinases which are essential for the viral
life cycle [1]. In entero- and rhinoviruses, the 2A proteinase
(2Apro) and the 3C proteinase are necessary to process the
viral polypeptide precursor into functional proteins [2]. In
addition, these proteinases cleave a limited number of cellular
proteins in order to subvert the cellular metabolism for opti-
mal viral replication [3].
In the early stage of the infection the main cellular targets
of 2Apro are the eukaryotic initiation factors (eIFs) eIF4GI
and eIF4GII. Each of the eIF4G homologues forms a com-
plex with eIF4E, which recognises the cap structure of cellular
mRNAs, and eIF4A, which functions as a helicase. This com-
plex is termed eIF4F. eIF4F is essential for bringing together
the capped mRNAs and the ribosomes (for reviews, see [4^9]).
eIF4GI and/or eIF4GII serve as sca¡olding proteins by bind-
ing eIF4E at the N-terminal domain, and eIF4A and eIF3, a
protein complex bound to the small ribosomal subunit, at the
C-terminal two-thirds of the molecule [10]. Cleavage of eIF4-
GI and eIF4GII by 2Apro abolishes translation initiation of
capped mRNAs, because it segregates the N-terminal domain
comprising the cap binding function from the rest of the fac-
tor complex. As a consequence, cellular translation initiation
is shut down [11,12]. The translation of most picornaviral
RNA, which is not capped, remains una¡ected or is even
stimulated by the cleavage of eIF4GI and eIF4GII as initia-
tion occurs internally at an internal ribosomal entry site
(IRES; for reviews, see [5,13^15]).
Numerous experiments have demonstrated that cleavage of
eIF4GI and/or eIF4GII is mediated by the 2Apro of entero-
and rhinoviruses [11,12,16]. However, the mode of this cleav-
age process is still being debated. In some reports it has been
concluded that the major eIF4G cleavage is not directly
caused by 2Apro but occurs instead via a yet unknown cellular
proteinase activated by 2Apro [17^20]. Recently, two cellular
eIF4GI cleavage activities (eIF4Gase-K and -L) have been
identi¢ed in poliovirus-infected HeLa cells [21]. These activ-
ities are also observed at low level in uninfected cells, in par-
ticular upon induction of apoptosis. In contrast, other experi-
ments have provided strong support for a direct cleavage of
eIF4G by the 2Apro [22^27]. However, in these experiments no
discrimination has been made between cleavage of eIF4GI
and of eIF4GII. In the present study a di¡erent experimental
approach has been taken to investigate the mode of eIF4GI
and eIF4GII cleavage by using a temperature-sensitive variant
of 2Apro (ts-2Apro) of human rhinovirus serotype 2 (HRV2).
The data obtained are consistent with a mechanism of direct
cleavage of eIF4GI and eIF4GII by the viral proteinase.
2. Materials and methods
2.1. Peptide cleavage
The TRPIITTA-para-nitroanilide (pNA) peptide was a gift from W.
Sommergruber (Boehringer Ingelheim, Austria). This chromogenic
peptide was found to be cleaved e⁄ciently by 2Apro [28^30].
2.2. Proteinase activity assay
Recombinant HRV2 2Apro (wt and ts) was puri¢ed as described
previously [23,31]. To examine the cleavage activity of 2Apro,
50 nmol pNA peptide was incubated with 30 nmol 2Apro in 500 Wl
reaction volume containing 50 mM Tris^HCl, pH 7.5, 100 mM NaCl,
10 mM dithiothreitol, 1 mM ethylenediaminetetra-acetate, and 5%
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glycerol (bu¡er A). The cleavage reaction was performed at 20‡C for
the time indicated and was monitored at 405 nm in a Hitachi U2000
spectrophotometer. To measure the thermosensitivity of ts-2Apro, the
proteinase was pre-incubated for 15 min either at 42‡C (restrictive
temperature) or at 20‡C (permissive temperature) and then added to
the pNA peptide.
2.3. Preparation of HeLa cell cytoplasmic extract
All manipulations were performed at 4‡C. 8U107 HeLa cells grown
in four 15 cm Petri dishes were washed twice with ice cold phosphate-
bu¡ered saline (PBS) containing 1.5 mM CaCl2 and 1.5 mM MgCl2
and once with PBS without Ca2þ and Mg2þ. The monolayer was
scraped o¡, taken up in PBS and centrifuged at 300Ug for 5 min.
The pellet was washed with 2 ml of homogenisation bu¡er HB
(250 mM sucrose, 3 mM imidazole, pH 7.4) and centrifuged again.
Cells were resuspended in 1 ml HB using a 1 ml pipette tip and were
lysed by passing through a 22G needle attached to a syringe for
several times. Disruption of cells was monitored by phase-contrast
microscopy. Nuclei were pelleted by centrifugation at 1000Ug for
10 min. The supernatant was then centrifuged for 30 min at
100 000Ug in a Beckman TLA100.3 rotor. The clear cytoplasmic
supernatant was frozen at 370‡C or used for in vitro cleavage assays
directly. Protein concentration was determined using the Pierce BCA
system [32].
2.4. eIF4GI and eIF4GII cleavage
Cleavage reaction of eIF4GI and eIF4GII was performed at 20‡C
in bu¡er A. To inactivate thermolabile proteins, HeLa cell cytoplas-
mic extract was pre-incubated for 15 min at 42‡C prior to the cleavage
reaction. Where indicated, wild-type 2Apro (wt-2Apro) and ts-2Apro
were incubated for 15 min at 42‡C. For each cleavage reaction,
40 Wg HeLa cell extract was mixed either with 0.5 Wg wt-2Apro or
with 1.0 Wg ts-2Apro in a ¢nal volume of 20 Wl and incubated at
20‡C for 1 h. After treatment for 15 min either at 42‡C or at 20‡C,
40 Wg of fresh HeLa cell extract was added and the samples were
incubated for 1 h at 20‡C. The reaction was terminated by adding
7 Wl 5ULaemmli sample bu¡er [33].
2.5. Western blot
Cleavage of eIF4GI and eIF4GII was analysed by Western blots.
Brie£y, aliquots of the cleavage reactions were separated on 6% poly-
acrylamide gels (SDS^PAGE) and blotted onto Immobilon P mem-
branes (Millipore, Bedford, MA, USA) [34]. The membranes were
blocked with 5% fat-free milk powder, 0.5% Tween 20 in PBS and
subsequently probed either with rabbit anti-eIF4GI antiserum (1:1000
dilution; raised against the C-terminal region of eIF4GI) or with
rabbit anti-eIF4GII antiserum (1:500 dilution; raised against the
N-terminal region of eIF4GII as previously described [35]).
3. Results
3.1. Thermosensitivity of the F130Y mutant of 2Apro
To assay the mode of eIF4GI and eIF4GII cleavage, use
was made of a thermolabile variant of 2Apro (ts-2Apro) of
HRV2 previously identi¢ed using a colorimetric screening as-
say [36]. This 2Apro contains a single amino acid replacement
at position 130, the phenylalanine residue of wt-2Apro being
changed to a tyrosine [31]. As a consequence of this F130Y
change the enzyme is rapidly inactivated at the restrictive
temperature of 42‡C, but retains its full activity upon incuba-
tion at 20‡C (permissive temperature).
To examine the activity of 2Apro a fast and convenient in
vitro assay has been established for rhinoviral 2Apro using a
chromogenic peptide resembling the cleavage sequence of
HRV2 2Apro in the HRV2 polyprotein (P8^P1) [28^30]. The
proteolytic enzyme activity can be followed by monitoring the
absorbance at 405 nm. The chromogenic peptide carries a
pNA group at its C-terminus which is cleaved o¡ by 2Apro.
Free pNA is determined by the absorbance at 405 nm.
Wt-2Apro and the F130Y mutant of 2Apro were incubated
with the peptide TRPIITTA-pNA and the kinetics of the
cleavage reaction were followed at 20‡C. In order to test for
thermosensitivity, wt-2Apro and the F130Y mutant were ¢rst
pre-incubated for 15 min at 42‡C or at 20‡C before assaying
for proteolytic activity with the TRPIITTA-pNA peptide at
20‡C. As seen in Fig. 1, the proteolytic activity of wt-2Apro
was only slightly a¡ected by pre-incubation at 42‡C. After
15 min more than 80% of the 2Apro cleavage activity could
still be observed as compared to the control. However, in
contrast to pre-incubation at 20‡C the F130Y mutant of
2Apro did not exhibit any peptide cleavage activity following
a 15 min pre-incubation at 42‡C. Even after a prolonged in-
Fig. 1. Rate of cleavage of pNA peptide by 2Apro. 30 nmol wt-2Apro or ts-2Apro were incubated with 50 nmol pNA peptide at 20‡C and cleav-
age was followed as change of absorbance at 405 nm. Both proteinases were pre-incubated for 15 min either at 20‡C or at 42‡C prior to pNA
peptide cleavage.
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cubation at 20‡C no increase of the absorbance at 405 nm
could be detected (data not shown). Thus the activity of the
F130Y mutant of 2Apro could be abolished completely by a
shift to the restrictive temperature of 42‡C. Therefore, the
thermosensitive F130Y mutant of 2Apro (ts-2Apro) was con-
sidered an ideal tool to examine the mode of eIF4GI and/or
eIF4GII cleavage.
3.2. Cleavage of eIF4GI and eIF4GII
The experimental approach for the elucidation of the mode
of eIF4GI and/or eIF4GII cleavage is based on the following
experimental protocol (Fig. 2): HeLa cell cytoplasmic extracts
were ¢rst pre-incubated for 15 min at 42‡C in order to inacti-
vate any endogenous thermosensitive proteins. The extracts
were then incubated with ts-2Apro for 1 h at the permissive
temperature of 20‡C in order to achieve complete cleavage of
eIF4GI and eIF4GII. Subsequently the mixture was shifted to
the restrictive temperature (42‡C) for 15 min in order to in-
activate ts-2Apro. If the ts-2Apro would have activated a hypo-
thetical ‘cellular proteinase X’ responsible for cleavage of
eIF4GI and/or eIF4GII, addition of new HeLa cell extract
and incubation at 20‡C would still lead to cleavage of the
newly added eIF4GI and eIF4GII, as the temperature shift
would have destroyed speci¢cally the activity of ts-2Apro. If,
on the other hand, ts-2Apro cleaves eIF4GI and eIF4GII di-
rectly, no cleavage of newly added eIF4GI and eIF4GII
should occur as the ts-2Apro has been inactivated at the re-
strictive temperature. Since wt-2Apro remains active at 42‡C,
eIF4GI and eIF4GII cleavage should occur under all condi-
tions in the control experiments with wt-2Apro carried out in
parallel.
The results of these experiments are presented in Fig. 3A,B.
Wt-2Apro used in lanes 1, 4 and 6 as well as ts-2Apro used in
lane 2 were pre-incubated for 15 min at 42‡C. Wt-2Apro or ts-
2Apro were added to the HeLa cell extracts as indicated and
the samples were incubated for 1 h at 20‡C. Under these
conditions more than 90% of eIF4GI and eIF4GII was
cleaved by wt-2Apro (lanes 1A and 1B) as well as by ts-
2Apro (lanes 3A and 3B). As expected, ts-2Apro inactivated
by pre-incubation at 42‡C for 15 min did not give rise to
any eIF4GI and eIF4GII cleavage product (lanes 2A and
2B). The small band close to the position of the eIF4GII
cleavage product in lane 2B is presumably due to cross-reac-
tive material as it is also present in the control sample not
treated with 2Apro (lane 8B). Addition of fresh HeLa cell
extract and incubation for 1 h at 20‡C resulted in cleavage
of the newly added eIF4GI and eIF4GII both with wt-2Apro
(lanes 4A and 4B) and with ts-2Apro (lanes 5A and 5B). A
temperature shift to 42‡C for 15 min of the sample with wt-
2Apro prior to the addition of new HeLa cell extract did not
a¡ect the enzymatic activity as newly added eIF4GI and eIF4-
GII were cleaved at 20‡C for 1 h (lanes 6A and 6B). In con-
Fig. 2. Scheme of the temperature shift experiment.
Fig. 3. Direct cleavage of eIF4GI (A) and eIF4GII (B) by HRV2
2Apro. Wt-2Apro used in lanes 1, 4 and 6 and ts-2Apro used in lane
2 as well as HeLa cell cytoplasmic extract were pre-incubated at
42‡C for 15 min. 40 Wg of HeLa cell extract was then incubated
with wt-2Apro or ts-2Apro at 20‡C for 1 h. Samples corresponding
to lanes 6, 7 and 8 were then heated at 42‡C for 15 min, while sam-
ples in lanes 3, 4 and 5 were kept at 20‡C. Subsequently, 40 Wg of
new HeLa cell extract was added as indicated (lanes 4^7) and incu-
bation continued for 1 h at 20‡C. HeLa cell extract without addi-
tion of 2Apro served as control (lane 8). The samples were analysed
on 6% SDS^PAGE, blotted onto Immobilon P membranes and
probed either with rabbit anti-eIF4GI antiserum (A) or with rabbit
anti-eIF4GII antiserum (B). Key: M, molecular weight marker;
C-cp, C-terminal cleavage product of eIF4GI; N-cp, N-terminal
cleavage product of eIF4GII.
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trast, in the parallel experiment with ts-2Apro using temper-
ature shift to 42‡C, no new eIF4GI and/or eIF4GII cleavage
products were obtained upon addition of new HeLa cell ex-
tract and incubation at 20‡C for 1 h (lanes 7A and 7B). As
shown by comparison of the bands in lanes 7A and 7B with
those in lanes 3A and 3B, the amounts of the cleavage prod-
ucts were the same, indicating that they were already pro-
duced during the ¢rst incubation at 20‡C. Thus, the shift to
the restrictive temperature of 42‡C of the incubation mixture
containing ts-2Apro prevented the production of new eIF4GI
and/or eIF4GII cleavage products in newly added HeLa cell
extract during the second incubation at the permissive temper-
ature. This lack of cleavage was obviously caused by the in-
activation of ts-2Apro at 42‡C. No evidence for the activation
of a cellular proteinase during incubation with 2Apro could be
obtained. These data support the notion that 2Apro cleaves
eIF4GI and eIF4GII directly without an intermediate step
of activation of a latent cellular proteinase.
4. Discussion
After the discovery that mutations in the 2Apro gene of
poliovirus prevent the host cell shut-o¡ of protein synthesis
and cleavage of eIF4G, many studies were carried out to
unravel the mechanism of eIF4G cleavage. Early experiments
were hampered by the fact that viral enzymes and cellular
initiation factors were not available in highly puri¢ed form.
The situation changed dramatically when viral enzymes as
well as initiation factors were expressed as recombinant pro-
teins in Escherichia coli and puri¢ed to homogeneity. It was
soon discovered that much of the controversy on the cleavage
mechanism was due to the fact that eIF4G itself as used in
several studies [37,38] is a poor substrate for 2Apro. Addition
of eIF4E increases the susceptibility to 2Apro cleavage by
about 100-fold [25]. This explains why eIF4G is a good sub-
strate for 2Apro when presented in the form of the eIF4F
complex [23]. Nevertheless, the e⁄ciency of eIF4G cleavage
in the in vitro reconstituted system using highly puri¢ed re-
combinant proteins was still considerably lower than that
found in the infected cell. E⁄cient eIF4G cleavage compara-
ble to that found in vivo was only obtained upon de novo
synthesis of 2Apro in a coupled in vitro transcription/trans-
lation system [27]. Yet, from these experiments alone it was
not possible to exclude that rapid 2Apro cleavage of eIF4GI
and eIF4GII requires the activation of an endogenous cellular
proteinase. Furthermore, Zamora et al. [21] have described
two cellular eIF4Gases in poliovirus-infected HeLa cells.
These eIF4Gases were also found at low level in uninfected
cells. Cellular eIF4Gase activity was increased upon induction
of apoptosis. As infected HeLa cells are known to induce at
least a partial apoptotic response, it is conceivable that eIF4-
Gases are also active upon poliovirus infection [39,40]. How-
ever, neither a relationship between 2Apro and activation of
the eIF4Gases nor the possible cleavage activity of the eIF4-
Gases on eIF4GII has been clari¢ed.
In order to assign a speci¢c function to 2Apro in the mode
of eIF4G cleavage a di¡erent approach has now been used
employing a ts-2Apro. A HeLa cell cytoplasmic extract was at
¢rst incubated with ts-2Apro at the permissive temperature to
allow complete cleavage of eIF4GI and eIF4GII. Following a
shift to the restrictive temperature to inactivate ts-2Apro, fresh
HeLa cell extract was added and the incubation was contin-
ued at the permissive temperature. Indeed no cleavage of
newly added eIF4GI and/or eIF4GII was observed. It can
therefore be concluded that the cleavage reaction requires
the continuous presence of active 2Apro unless it is assumed
that a hypothetical cellular proteinase becomes heat labile
upon activation, which at present cannot be excluded. How-
ever, the most straightforward interpretation of the data is
consistent with a model of direct cleavage of eIF4GI and
eIF4GII by 2Apro. The recently described cellular eIF4Gases
are apparently not activated under our cleavage conditions as
there is no cleavage in the absence of 2Apro.
A mechanism of direct cleavage by 2Apro also solves the
problem of di¡erential cleavage of eIF4GI and eIF4GII as
observed during picornavirus infection. In contrast to
HRV2, where both eIF4GI and eIF4GII are cleaved at a
comparable rate [41], the rates of cleavage of eIF4GI and
eIF4GII di¡er signi¢cantly during poliovirus and HRV14 in-
fection [12,42]. Both viruses cleave eIF4GII much more slowly
than eIF4GI. This di¡erence in sensitivity would be di⁄cult to
reconcile in any model of indirect cleavage via activation of a
latent cellular proteinase. However, this di¡erence can easily
be explained by the di¡erent cleavage speci¢cities of the
2Apros of the various viruses.
eIF4GI and eIF4GII represent ideal targets for the shut-
down of host cell protein synthesis by a virus. Both are scaf-
folding proteins involved in organisation of the protein syn-
thesis machinery complex by binding di¡erent initiation fac-
tors involved in cellular mRNA recognition. Cleavage by
2Apro sequesters the cap binding functional domain. By this
direct eIF4G cleavage, host cell protein synthesis is shut down
and IRES-dependent initiation of the picornaviral RNA can
proceed without activation of an additional cellular protein-
ase. This strategy guarantees optimal expression of the picor-
naviral genome under conditions of maximal suppression of
cellular protein synthesis.
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